The Grocery Reform And Safety (GRAS) Act amends the Federal Food, Drug, and Cosmetic Act to remove the longstanding practical exemption that let firms treat ingredients as “generally recognized as safe” (GRAS) without prior FDA review. The bill requires manufacturers (and others bringing substances into interstate commerce) to submit a formal notice to FDA before treating a new use or newly introduced substance as GRAS, supply specified supporting data, and may use the substance only after FDA issues a written “no‑objection” statement.
FDA must post notices publicly and allow a 60‑day comment window.
The bill also creates a recurring reassessment program: within three years and at least every three years thereafter FDA must systematically reassess the safety of at least 10 substances or classes (including pre‑existing GRAS substances, color additives, and food contact substances). The statute authorizes fees to cover FDA’s review work, gives FDA authority to require industry safety evaluations, and attaches civil monetary penalties for noncompliance.
For businesses, the act replaces informal self‑affirmation with a structured, resource‑backed regulatory process that raises transparency and compliance costs and exposes previously unreviewed ingredients to revocation and market disruption.
At a Glance
What It Does
The bill requires premarket submission of a GRAS notice for any new use or newly marketed food substance and specifies the data that notice must include (identity, manufacturing, exposure and safety analyses, cumulative effects, carcinogenicity and developmental/reproductive toxicity assessments). FDA must issue a written no‑objection or objection within 180 days (with a single 90‑day extension) and will publish notices and supporting data with a 60‑day public comment period.
Who It Affects
Ingredient manufacturers, traders, and food companies that introduce or receive substances in interstate commerce will face new premarket obligations; contract testing labs, consultancy firms, and private GRAS panels will see demand for more formalized dossiers; FDA will need staffing and fee‑funding to implement reviews and periodic reassessments.
Why It Matters
The Act replaces the de facto self‑affirmation pathway that many companies used to market additives without FDA signoff with a mandatory, transparent review process and a statutory reassessment cycle — a structural change that raises compliance costs, shortens regulatory ambiguity, and creates a mechanism for revoking previously unreviewed GRAS determinations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The GRAS Act rewrites how substances used in food move from theory to market. It amends the definition of food additive so that the GRAS category is explicitly addressed within that definition and clarifies the evidentiary standard for being ‘‘generally recognized as safe,’’ distinguishing substances subject to modern scientific procedures from those whose safety claim rests on long common use before 1958.
That change effectively puts GRAS substances on a statutory footing that subjects them to the same statutory section (section 409) that governs food additives.
The bill creates a new notification program. If a firm wants to treat a substance as GRAS for a new use or markets a substance not previously used in U.S. foods, it must submit a notice to FDA containing full supporting data: chemical identity and composition, manufacturing controls, intended use and exposure estimates, cumulative exposure analyses, hazard and dose‑response evidence, and explicit analyses showing lack of carcinogenicity or reproductive/developmental toxicity (including endocrine modes of action).
FDA will accept notices in the format set out in existing regulations (21 C.F.R. part 170, subpart E), post them in a single web location, and open a minimum 60‑day public comment period. A company may only proceed to use the substance under the conditions in its notice if FDA issues a written statement that it does not object.A parallel reassessment program requires FDA, within three years and then at least every three years, to reassess the safety of at least ten substances or classes — examples listed include previously marketed GRAS substances, color additives, prior‑sanctioned substances, food contact substances, and additives approved under subsection (c).
As part of those reassessments FDA can compel manufacturers and distributors to produce updated safety evaluations covering updated exposure estimates, cumulative effects, safety factors, and modern endpoints (carcinogenicity, reproductive and developmental toxicity). If reassessment reveals safety concerns, FDA can revoke a prior no‑objection statement and publish the revocation.To resource this workload the bill amends FDA’s fee authority so fees can be charged to petitioners and notice filers and to parties subject to reassessments, with an express provision that fee amounts cover the Secretary’s estimate of 100 percent of the relevant review costs for that fiscal year.
The bill also creates a civil penalty mechanism for violations of the reassessment notice requirements and authorizes appropriations to carry out the new notification and reassessment duties. Finally, the bill adds statutory definitions for key terms (carcinogenic, cumulative effects, developmental and reproductive toxicity, conflict of interest, class, food contact substance, and new use) that set the frame for what evidence FDA must consider and what it can require from industry.
The Five Things You Need to Know
FDA must issue a written 'no‑objection' or an objection to a GRAS notice within 180 days of acceptance, with one possible 90‑day extension — use is allowed only after a written no‑objection.
Notices and all supporting data accepted by FDA will be posted in a single FDA website location and open to at least 60 days of public comment before finalization.
Every three years FDA must reassess at least 10 substances or classes (including pre‑existing GRAS substances, color additives, food contact substances, and prior‑sanctioned substances) and may require industry to submit updated safety evaluations.
The bill authorizes FDA to collect fees to fully cover the cost of reviewing GRAS notices and conducting reassessments (the statute ties fee assessments to an estimate of 100% of activity costs) and authorizes appropriations to support implementation.
The statute creates a civil monetary penalty for violations of the reassessment notification requirement and provides explicit statutory definitions for carcinogenicity, cumulative effects, developmental and reproductive toxicity, and conflict of interest that guide review expectations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name as the Grocery Reform And Safety Act (GRAS Act). This is purely nomenclature but signals intent to recast GRAS policy as a consumer‑protection reform rather than an industry self‑regulation framework.
Remove GRAS exemption and clarify GRAS standard
The bill amends the statutory definition of 'food additive' to include substances that are generally recognized as safe, and replaces the prior textual carve‑out that had, in practice, allowed GRAS substances to escape the food additive framework. It inserts a specific definition of 'generally recognized as safe' that requires demonstration by scientific procedures (or, for pre‑1958 food uses, by common use). The practical effect is to place GRAS determinations within the statutory structure Congress uses to regulate food additives, making them subject to the procedural and substantive tools of section 409.
Mandatory GRAS notification program and public process
Creates a mandatory premarket notice for any person bringing a substance into interstate commerce who intends to treat it as GRAS for a new use or any substance not marketed in foods before enactment. The provision lists required contents of a notice — identity/composition, manufacturing controls, exposures, cumulative effects, dose‑response, safety factor analyses, and explicit assessments for carcinogenicity and reproductive/developmental toxicity — and mandates FDA acceptance in the format already prescribed by regulation. It requires FDA to publish notices and supporting data, open a 60‑day comment period, and to issue a written no‑objection or objection within a firm timetable (180 days with one 90‑day extension). The clause also empowers FDA to object if notices lack data, if experts have conflicts of interest, or if the evidence fails to support safety under the proposed conditions of use.
Systematic reassessments and authority to require safety evaluations
Mandates that, not later than three years after enactment and at least every three years thereafter, FDA systematically reassess the safety of at least ten named substances or classes (including previously marketed GRAS substances, color additives, food contact substances, prior‑sanctioned substances, and additives approved under subsection (c)). During reassessments FDA can require companies to perform and submit updated safety evaluations with modern exposure estimates, cumulative assessments, and endpoints such as endocrine‑mediated developmental or reproductive toxicity. If FDA finds safety concerns it may revoke a prior no‑objection statement and must publish that revocation; violations of reassessment notification duties carry civil penalties under section 307.
New statutory definitions to guide review
Adds definitions for carcinogenic, class, conflict of interest, cumulative effects, developmental toxicity, food contact substance, new use, and reproductive toxicity. These definitions narrow ambiguity about what evidence FDA should evaluate — for example, defining carcinogenic by induced cancer in humans/animals or authoritative body findings, and defining cumulative effects as combined health effects of chemically or pharmacologically related substances — and give FDA a statutory foothold to require specific endpoints be considered during notice review and reassessments.
Fee authority expanded for GRAS notices and reassessments
Expands FDA’s fee authorities to include charges for persons filing GRAS notices and for those subject to reassessments, and requires FDA to base certain fee categories on an estimate of 100% of review costs for the fiscal year. It also updates historical fiscal year references to current years. The change formalizes a pay‑for‑review model intended to resource the increased workload of notice reviews and periodic reassessments.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers and public‑health advocates — gain greater transparency and routine reassessment of substances marketed without prior FDA review, creating more opportunities to surface safety concerns and trigger corrective action.
- FDA and public regulators — obtain explicit statutory authority, firmer timelines, and fee resources to review GRAS claims and to compel data during reassessments, reducing prior reliance on voluntary industry submissions.
- Researchers and independent testing labs — increased demand for up‑to‑date safety studies, exposure assessments, and cumulative‑effects analyses will create work and clearer standards for what data FDA expects.
- Food companies that invest in robust safety dossiers — benefit from a predictable, public no‑objection process that can create a clearer market advantage and reduce later regulatory uncertainty compared with firms that relied on informal self‑affirmation.
Who Bears the Cost
- Ingredient manufacturers and importers — bear immediate compliance costs to prepare detailed GRAS notices, fund new studies (exposure, reproductive/developmental endpoints, cumulative effects), and may face delays or market exclusion until FDA issues a no‑objection.
- Small businesses and niche suppliers — have fewer resources to support the dossier and testing burden, increasing the risk that small suppliers are priced out or that downstream reformulation costs rise for small food producers.
- FDA operations and Congress — while fees are authorized, FDA must stand up systems to process notices, manage public posting and comments, and run reassessments; unfunded transition costs and implementation choices will fall on agency budgets and priorities.
- Supply chains and processors — face knock‑on costs if FDA revokes prior no‑objection statements or requires reformulation, potentially disrupting sourcing and inventory already in the market.
Key Issues
The Core Tension
The central dilemma is trade‑off between stronger, transparent premarket and periodic safety oversight and the regulatory friction that creates for market entry, innovation, and proprietary data: mandating full public dossiers and agency review protects consumers and standardizes science, but it also imposes study costs, possible disclosure of trade secrets, and the risk that FDA revocation will force sudden reformulation — a classic safety‑vs‑innovation policy tension with no algorithmic solution.
The bill stacks important implementation choices on top of statutory language that will require regulatory design. First, the public posting requirement increases transparency but raises concrete trade‑secret and confidential‑business‑information issues: the statute requires 'supporting data and information' be publicly available in a single location, so FDA will need a robust, legally defensible approach to redaction and CBI claims to avoid both disclosure of proprietary formulations and litigation.
Second, the conflict‑of‑interest standard is left to FDA guidance; how aggressively FDA defines and enforces conflict rules will shape whether industry expert panels remain useful or are disqualified en masse, potentially shifting the evidentiary burden to costly new studies.
Operationally, the statutory 180‑day timeline (plus one 90‑day extension) creates a hard expectation for decision speed, but the volume of notices and the recurring reassessment mandate could quickly outstrip FDA capacity, producing either backlogs or pressure to rely on less comprehensive reviews. The fee language ties fees to an estimate of 100% of activity costs, but budgets, hiring lags, and litigation risk mean fees alone may not immediately produce review capacity; the transition period is therefore a risk window for both industry and regulators.
Finally, the reassessment authority covers substances marketed before enactment — the bill allows FDA to require notifications from products marketed before, on, and after enactment — which raises legal and fairness questions about retroactive obligations and how FDA will prioritize substances for reassessment without disrupting markets.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.